Kathleen A. McGuire
YOU?
Author Swipe
View article: Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications
Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications Open
The cellular thermal shift assay (CETSA®) is a target engagement method widely used for preclinical characterization of small molecule compounds. CETSA® has been used for semi-quantitative readouts in whole blood with PBMC isolation, and q…
View article: 999 The PTPN2/N1 small molecule inhibitor ABBV-CLS-484 promotes NK cell activity driving primary tumor regression and preventing metastasis
999 The PTPN2/N1 small molecule inhibitor ABBV-CLS-484 promotes NK cell activity driving primary tumor regression and preventing metastasis Open
Background The tyrosine phosphatases PTPN2 and PTPN1 negatively regulate several signaling pathways in immune and tumor cells. We previously demonstrated that oral administration of our recently discovered active site PTPN2/N1 small molecu…
View article: 1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity Open
Background Immune checkpoint blockade is effective for a subset of patients across many cancers, but most patients are refractory to current immunotherapies and new approaches are needed to overcome resistance.1 2 The protein tyrosine phos…
View article: Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications
Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications Open
The cellular thermal shift assay (CETSA®) is a target engagement method widely used for preclinical characterization of small molecule compounds. CETSA® has been used for semi-quantitative readouts in whole blood with PBMC isolation, and q…
View article: 1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activity
1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activity Open
Background The tyrosine phosphatases PTPN2 and PTPN1 are important negative regulators of immune signaling pathways and genetic deletion of these proteins in tumor or immune cells has been shown to overcome unresponsiveness to checkpoint b…
View article: Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses Open
PD-1 expression marks activated T cells susceptible to PD-1–mediated inhibition but not whether a PD-1–mediated signal is being delivered. Molecular predictors of response to PD-1 immune checkpoint blockade (ICB) are needed. We describe a …
View article: VISTA is an activating receptor in human monocytes
VISTA is an activating receptor in human monocytes Open
As indicated by its name, V-domain Ig suppressor of T cell activation (VISTA) is thought to serve primarily as an inhibitory protein that limits immune responses. VISTA antibodies can dampen the effects of several concomitantly elicited ac…
View article: New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission
New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission Open
The data suggest that focusing the immune response against defined epitopes displayed on the viral capsid is an effective strategy for transmission-blocking vaccine development.
View article: PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity Open
It is unclear whether PD-L1 on tumor cells is sufficient for tumor immune evasion or simply correlates with an inflamed tumor microenvironment. We used three mouse tumor models sensitive to PD-1 blockade to evaluate the significance of PD-…